Therapy Areas: Inflammatory Diseases
XBiotech signs up first patient for hidradenitis suppurativa trial
10 July 2018 -

XBiotech Inc. (NASDAQ: XBIT) has enrolled the first patient in its Phase 2 open label, dose escalation clinical study evaluating its subcutaneous formulation of MABp1 in patients with moderate to severe hidradenitis suppurativa (HS), the company revealed on Tuesday.

HS is a chronic, inflammatory skin disorder that causes abscesses and scarring on the skin, affecting areas rich in apocrine glands such as the armpits, breasts and groin. Nodules appear in the affected areas and progressively become swollen with spontaneous rupture and release of pus.

Up to 4% of the global population is thought to be affected. Traditional treatments comprise of antibiotics, anti-androgens and surgery.

XBiotech is developing a human-derived antibody (MABp1) which neutralises IL-1 alpha, an inflammatory cytokine that plays a key role in the pathophysiology of a wide range of inflammatory skin disorders.

Three Phase II studies have already been completed in acne, psoriasis and pyoderma gangrenosum.

An earlier Phase 2 study evaluating MABp1 for the treatment of HS met its primary endpoint, demonstrating significant improvement of HS patients treated with MABp1 compared to control after 12 weeks of therapy. While this previous HS study involved intravenous infusion of the antibody therapy, the new trial will be the first use of the subcutaneous formulation of MABp1 in HS.

Login
Username:

Password: